This week, Orexigen's (NASDAQ:OREX) obesity drug, Contrave, is up for Food and Drug Administration approval.
The biotech originally tried to gain approval for Contrave a few years ago, but the FDA rejected the drug, asking for a clinical trial to ensure there weren't heart problems. Orexigen ran the trial, and the interim data ruled out an increase in heart problems above a certain threshold. At this point, an approval seems likely.
It remains to be seen whether Contrave will be able to succeed where Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq and VIVUS's (NASDAQ:VVUS) Qsymia have struggled. Contrave has better efficacy Belviq and a better safety profile than Qsymia. Unfortunately, with the heart trial still ongoing, the interim data isn't expected to be on the label.
Watch the video below to see what senior biotech specialist Brian Orelli and health-care analyst David Williamson think of the competition between Orexigen, Arena Pharmaceuticals, and VIVUS.
Multi-bagger potential, no binary event required
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
Brian Orelli and David Williamson have no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.